Mass Blue Cross Blue Shield Blue Basic Immunization Coverage
September 16, 2021
This notice has been updated to include information about additional doses and boosters.
In the face of the COVID-19 pandemic, pharmaceutical companies have moved to produce vaccines. The Food and Drug Administration (FDA) awarded Emergency Use Authorization (EUA) to three pharmaceutical companies for their vaccines: Pfizer
on Dec. 11, 2020 and Moderna on Dec. 18, 2020 and Janssen Pharmaceutical Companies of Johnson & Johnson on Feb. 27, 2021. On Aug. 23, 2021, the FDA granted full approval of the Pfizer COVID-19 vaccine for ages 16 and older. The Pfizer vaccine, known as Comirnaty is also available under EUA for ages 12-15. See the FDA website for prescribing information.
Federal and state health officials are working with the medical community to distribute the COVID-19 vaccine.
Booster Shots and Additional Doses: The federal government requires us to cover the COVID-19 vaccine at no cost share through the end of the public health emergency (PHE). This includes COVID-19 booster shots and additional doses. The Centers for Disease Control and Prevention (CDC) provides guidance on the administration of the vaccine. At the end of the PHE, we will provide updates on our coverage.
Initially, thefederal government will pay for the vaccine. Blue Cross and Blue Shield of Illinois (BCBSIL), or self-funded groups, will coveradministration of the vaccine as noted below. The administration of additional doses and boosters will be covered in the same way as the original doses of the vaccine during the PHE:
Fully insured:
- Vaccine and administration covered as a preventive service with no cost-share to members at in-network providers
- Vaccine and administration covered with no cost-share to members if delivered at out-of-network providers through the end of the public health emergency
Self-funded employer groups:
- Non-grandfathered self-funded employer groups - vaccine and administration covered as a preventive service with no cost-share to members at in-network providers
- Vaccine and administration covered at no cost-share to members at out-of-network providers through the end of the public health emergency
- Self-funded employer groups that don't cover preventive vaccines through their pharmacy benefit must cover the vaccine through their medical benefit
- Grandfathered plans are not required to cover preventive services, including the COVID-19 vaccine
Medicare
- For 2020 and 2021, Medicare payment for the COVID-19 vaccine and its administration will be through the original fee-for-service Medicare program.
- Submit claims for administering the COVID-19 vaccine to the Centers for Medicare and Medicaid Services (CMS) Medicare Administrative Contractor (MAC) using product-specific codes for each vaccine approved.
- Members will have no cost-sharing on vaccines from in- and out-of-network providers through Dec. 31, 2021.
Medicaid
- Most Medicaid members will have no cost-sharing on vaccines from in- and out-of-network providers. See the CMS Medicaid toolkit
for more details. - The Illinois Department of Healthcare and Family Services (HFS) has posted the current coding and rates, as well as billing guidance for Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs) and Encounter Rate Clinics (ERCs) related to the COVID-19 vaccine and its administration.
Reimbursement:
- In-network providers will be reimbursed for the administration fee based on contracted rates.
- Out-of-network (OON) providers will be reimbursed based on established OON reimbursement policy that follows Medicare rates.
Balance billing: Providers are prohibited from billing patients for the vaccine or its administration, including balance billing, if the provider received the vaccine at no cost from the government.
Coding claims: CMS and the American Medical Association (AMA) have identified the codes to use in submitting claims. For more information, see CMS' guidance.
Whenbilling a vaccine administration code with an office visit, if the vaccine isnot the primary purpose of the office visit,bill the vaccine on aseparate claim.
| Code | Use | Description |
| M0201 | Admin | COVID-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only COVID-19 vaccine administration is performed at the patient's home |
| D1701 | Admin | Pfizer-BioNTech COVID-19 vaccine administration – first dose |
| D1702 | Admin | Pfizer-BioNTech COVID-19 vaccine administration – second dose |
| D1703 | Admin | Moderna COVID-19 vaccine administration – first dose |
| D1704 | Admin | Moderna COVID-19 vaccine administration – second dose |
| D1707 | Admin | Janssen/Johnson & Johnson COVID-19 vaccine administration |
| 0001A | Admin | Pfizer-BioNtech COVID-19 vaccine administration – first dose ADM SARS-CoV-2 30MCG/0.3ML 1ST |
| 0002A | Admin | Pfizer-BioNtech COVID-19 vaccine administration – second dose ADM SARS-CoV-2 30MCG/0.3ML 2ND |
| 0003A | Admin | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose |
| 0011A | Admin | Moderna COVID-19 vaccine administration – first dose ADM SARS-CoV-2 100MCG/0.5ML1ST |
| 0012A | Admin | Moderna COVID-19 vaccine administration – second dose ADM SARS-CoV-2 100MCG/0.5ML2ND |
| 00013A | Admin | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose |
| 0031A | Admin | Janssen/Johnson & Johnson - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose |
| 91300 | Vaccine | Pfizer-BioNtech COVID-19 vaccine SARS-CoV-2 VAC 30MCG/0.3ML IM |
| 91301 | Vaccine | Moderna COVID-19 vaccine SARS-CoV-2 VAC 100MCG/0.5ML IM |
| 91303 | Vaccine | Janssen/Johnson & Johnson - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use |
Dosage: Candidate vaccines may require one or two doses. The Pfizer and Moderna vaccines require two doses. The Janssen/Johnson & Johnson vaccine is one dose. The Janssen/Johnson & Johnson vaccine is one dose. Guidance on additional doses is evolving. Follow CDC guidelines.
More information:
We continue to monitor information provided by the CDC and other government and health officials. We'll provide updates when we have them. For the latest information on COVID-19, we recommend visiting the CDC's COVID-19 website.
Source: https://www.bcbsil.com/provider/education/education-reference/news/2021-news-and-updates/09-16-2021-covid-vaccines-and-coverage
0 Response to "Mass Blue Cross Blue Shield Blue Basic Immunization Coverage"
Publicar un comentario